Afinitor UK Particular Patient Supplies for Advanced Neuroendocrine Tumors (NETs) Abstract #233

Introduction: The PI3/Akt/mTOR pathway is activated by IGF-1 in NETs. mTOR regulates signalling downstream of IGF-1R1: Afinitor and Sandostatin may synergistically arrest growth and secretory activity in NETs.
Aim(s): The Afinitor (mTOR inhibitor) particular patient supplies program treated 40 patients with advanced NETs in the UK from May 2008 to December 2010.
Materials and methods: The incidence of NETs is rising with rates approaching three per 100,000 (Ramage et al, Gut, 2005). Novartis Oncology UK provided the oral mTOR inhibitor, Afinitor, for unsolicited requests to patients with advanced NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mr Jonathan S Chambers
Authors: Chambers J

To read results and conclusion, please login ...

Further abstracts you may be interested in

#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#777 Laparoscopic Surgery of Functioning Neuroendocrine Tumors of Pancreas
Introduction: Laparoscopic surgery is a feasible technique for benign pancreatic pathologies and has been increasingly reported for neuroendocrine tumors of the pancreas.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Viktor Shkarban
#1087 Gastro-Entero-Pancreatic Mixed Adenoneuroendocrine Tumors. Report of Four Cases.
Introduction: Mixed adenoneuroendocrine carcinomas (MANECs) is an uncommon entity with ill-defined clinicopathologic characteristics.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Georgia Karayannopoulou
#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anna Kuznetsova